Gadoteridol

From Wikipedia, the free encyclopedia
Gadoteridol
Gadoteridol.svg
Clinical data
Other names(10-(2-(hydroxy-κO)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3)-κN1,κN4,κN7,κN10,κO1,κO4,κO7)-gadolinium
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration
IV
ATC code
Legal status
Legal status
Identifiers
  • gadolinium(+3) cation; 2-[4-(2-hydroxypropyl)-7,10-bis(2-oxido-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H29GdN4O7
Molar mass558.69 g·mol−1
3D model (JSmol)
  • [Gd+3].[O-]C(=O)CN1CCN(CCN(CCN(CC(O)C)CC1)CC([O-])=O)CC([O-])=O
  • InChI=1S/C17H32N4O7.Gd/c1-14(22)10-18-2-4-19(11-15(23)24)6-8-21(13-17(27)28)9-7-20(5-3-18)12-16(25)26;/h14,22H,2-13H2,1H3,(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3 checkY
  • Key:DPNNNPAKRZOSMO-UHFFFAOYSA-K checkY
 ☒NcheckY (what is this?)  

Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance.

References[]

  • Bracco Diagnostic Inc. (May 2007). "Gadoteridol (ProHance) prescribing information (revised May 2007)". DailyMed. U.S. National Library of Medicine. Retrieved 2008-07-13.
Retrieved from ""